vimarsana.com
Home
Live Updates
Kintor Pharma Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne : vimarsana.com
Kintor Pharma Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne
/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...
Related Keywords
China ,
Suzhou ,
Jiangsu ,
Kintor Pharma ,
Prnewswire Kintor Pharmaceutical Limited Pharma ,
Drug Administration ,
Kintor Pharmaceutical ,
China Center ,
Pharmaceutical Limited ,
Proteolysis Targeting Chimera ,
Youzhi Tong ,
Chief Executive Officer ,
Drug Evaluation ,
vimarsana.com © 2020. All Rights Reserved.